BPC November 12 update

Oncorus ONCR Phase 1 data; Catalyst CBIO Halt hemophilia assets development

Pre-Market Updates

Oncorus, Inc. (NASDAQ: ONCR) presented data from its ongoing Phase 1 trial of ONCR-177 to treat solid tumors. Data reported one partial response, one Investigator-reported clinical response, and one patient with stable disease.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced a decision to halt the clinical development of MarzAA and seek a buyer for its hemophilia assets. Catalyst plans to focus its resources on its complement therapeutics and protease medicines platform.

Compugen Ltd. (NASDAQ: CGEN) announced the presentation of preliminary results from its Phase 1 study of COM902 to treat solid tumors. The best treatment response was stable disease (SD) which was reported in 9 patients (50%), with 6 patients (67%) having confirmed SD and 3 patients (17%) with SD of at least 6 months.

Johnson & Johnson (NYSE: JNJ) announced that it will separate its Consumer Health business from the larger company. The planned separation would create two separate public companies.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announced updated results from its Phase 1/1b trial of mupadolimab to treat solid tumors. The results noted tumor regression was seen in five patients who had progressive disease as the best response to the most recent therapy, which included anti-PD(L)1 therapy.

Pre-Market Advancers

CompanyPriceChange
PTN
Palatin Technologies Inc.
$0.79+0.2324  +41.68%
STSA
Satsuma Pharmaceuticals Inc.
$5.96+0.71  +13.52%
BYSI
BeyondSpring Inc.
$16.25+1.9  +13.24%
ACHL
Achilles Therapeutics plc
$5.39+0.55  +11.36%
OGEN
Oragenics Inc.
$0.60+0.0488  +8.87%
DRMA
Dermata Therapeutics Inc.
$2.93+0.23  +8.52%
UNCY
Unicycive Therapeutics Inc.
$3.16+0.24  +8.22%
WDNA
WisdomTree BioRevolution Fund
$26.00+1.8493  +7.66%
LOGC
LogicBio Therapeutics Inc.
$3.15+0.21  +7.14%
URGN
UroGen Pharma Ltd.
$13.00+0.86  +7.08%

Pre-Market Decliners

CompanyPriceChange
NAVB
Navidea Biopharmaceuticals Inc.
$1.15-0.15  -11.54%
IKT
Inhibikase Therapeutics Inc.
$1.91-0.15  -7.28%
PSTI
Pluristem Therapeutics Inc.
$2.52-0.17  -6.32%
BPTS
Biophytis SA
$5.40-0.36  -6.25%
APVO
Aptevo Therapeutics Inc.
$12.26-0.81  -6.20%
ANGN
Angion Biomedica Corp.
$3.54-0.2099  -5.60%
PBLA
Panbela Therapeutics Inc.
$1.86-0.11  -5.58%
VLON
Vallon Pharmaceuticals Inc.
$5.05-0.26  -4.90%
RVPH
Reviva Pharmaceuticals Holdings Inc.
$3.60-0.18  -4.76%
CRNX
Crinetics Pharmaceuticals Inc.
$23.25-1.15  -4.71%